The present disclosure relates to a method for labeling a radioisotope, a radiolabeling compound, a kit including the same, and a method for labeling a radioisotope, including: providing a diaminophenyl compound represented by Chemical Formula I below and including a biomolecule, a fluorescent dye or a nanoparticle compound bound thereto; and reacting the diaminophenyl compound and a radioisotope-labeled aldehyde compound represented by Chemical Formula II below at room temperature; and a related technology:

##STR00001## in Chemical Formula I, A is CH.sub.2 or O; a is 0 or an integer of 1 to 10; X is CH.sub.2 or CONH; Y is CH.sub.2 or

##STR00002##

and Z is the biomolecule, the fluorescent dye or the nanoparticle compound,

##STR00003## in Chemical Formula II, b is 0 or an integer of 1 to 10; and L is CH.sub.2 or CONH; and Q is or

##STR00004## M, M and M in Q are radioisotopes.

The present invention relates to various compositions and methods of using these compositions for imaging natriuretic peptide receptors using, for example, positron emission tomography.

The present invention relates to a stable pharmaceutical composition of tetrofosmin or pharmaceutically acceptable salts thereof. It also relates to a lyophilized non-radioactive kit which upon reconstitution with .sup.99mTc-pertechnetate solution gives a stable .sup.99mTc-tetrofosmin radiopharmaceutical composition. It also provides process for the preparation of said radiopharmaceutical compositions and their use in diagnostic imaging procedures. The compositions provide desirable technical attributes such as stability, high radiochemical purity (RCP) and desired bio-distribution.

Some embodiments relate to therapeutic radioisotopic particles. In some embodiments, the therapeutic particles are radiolabeled with therapeutic radioisotopes. In some embodiments, the therapeutic particles can be in the treatment of cancer of the liver. In some embodiments, the therapeutic particles are radiolabeled with therapeutic radioisotopes. In some embodiments, the therapeutic radioisotope is directly coupled to a surface of a substrate of the particle.

The invention is directed to a body comprising oxides of lanthanides, in particular holmium oxide (Ho.sub.2O.sub.3), which are supported on a sulphur containing carbon based particle and to a process for producing said body.

The disclosure pertains to a strontium-90 sealed radiological or radioactive source, such as may be used with treatment of the eye or other medical or industrial processes. The sealed radiological source includes a radiological insert within an encapsulation. The encapsulation may include increased shielding in the center thereof.

The present disclosure provides a method and an apparatus for producing astatine-211 from alpha-particle bombardment of bismuth-209. The disclosure also relates to a method and apparatus of producing other radionuclides from target nuclides. The apparatus includes a plate having a recessed portion. The recessed portion has a generally inert surface of ceramic or metal, preferably aluminium oxide that does not react with molten bismuth. A bismuth target is placed in the recessed portion and held therein by a foil cover. The foil has a melting temperature greater than target nuclide (i.e., for bismuth, >271 C.). The foil and target nuclide are held in the recessed portion by a cover that is fastened over the foil. The cover has an aperture to allow a beam of radiation, such as alpha particles, from a cyclotron or other accelerator to pass through the cover to the foil and target nuclide.

Systems and methods for enhanced diagnosis of transthyretin-related cardiac amyloidosis in a subject are disclosed. The systems and methods may use both SPECT imaging data as well as an anatomical imaging data, such as computed tomography (CT) data, to produce a combined image. Within the combined image, the radiotracer uptake between two volumes of interests are compared, one of which may represent the left ventricle of the subject and the other may represent the blood pool retention of the subject. Combining the anatomical imaging data with SPECT data enables better anatomical delineation and helps in avoiding areas with coronary or lymph node calcifications and overlying soft tissue and bony pathologies.

The present invention relates to formulations of radiolabelled compounds that are of use in radiotherapy and diagnostic imaging.

There is provided a process for the preparation of a pharmaceutical composition comprising an .sup.18F-labelled gas selected from the group consisting of .sup.18F-labelled sulphur hexafluoride ([.sup.18F]SF.sub.6) and .sup.18F-labelled carbon tetrafluoride ([.sup.18F]CF.sub.4), comprising the steps: a) Filling a target with a gas mixture comprising a fluorinated gas selected from the group consisting of sulphur hexafluoride (SF.sub.6) and carbon tetrafluoride (CF.sub.4); b) Irradiating the gas mixture of step a) with protons with energies from 0.1 to 50 MeV. The pharmaceutical composition obtainable by the process and its uses in diagnosis, prognosis and lung function studies based on positron emission tomography (PET) are also claimed.